Mycophenolate sodium

DRUG16 trials

Sponsors

Novartis Pharma AG, Consorci Mar Parc De Salut De Barcelona, Novartis Pharmaceuticals, University Hospital Muenster, Cedars-Sinai Medical Center

Conditions

+/- VAcute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdult Diffuse Large Cell LymphomaAnaplastic Large Cell LymphomaBurkitt LymphomaChronic Kidney Disease

Phase 1

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

CompletedNCT00542763

University Hospital MuensterPrimary Sjogren's Syndrome

Start: 2005-04-30End: 2007-09-30Updated: 2007-10-11

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

RecruitingNCT04375631

Fred Hutchinson Cancer CenterRecurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome +6

Start: 2020-12-03End: 2027-03-17Target: 120Updated: 2026-03-05

Phase 2

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

CompletedNCT00423098

Novartis PharmaceuticalsLupus Nephritis

Start: 2007-02-28End: 2009-11-30Updated: 2011-06-28

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

RecruitingNCT04195633

Fred Hutchinson Cancer CenterAcute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +16

Start: 2021-01-25End: 2029-03-12Target: 60Updated: 2026-02-27

An adaptive, randomized, double-blind, dose exploration, parallel group, placebo controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V

RecruitingCTIS2023-509332-26-00

Novartis Pharma AGLupus Nephritis Class III-IV, +/- V

Start: 2023-02-16Target: 48Updated: 2025-12-30

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

RecruitingNCT07412470

SanofiKidney Transplant Rejection

Start: 2026-03-13End: 2033-08-15Target: 526Updated: 2026-03-27

Phase 3

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

TerminatedNCT01015456

Chulalongkorn UniversityLupus Nephritis

Start: 2010-01-31End: 2013-01-31Updated: 2014-10-10

Everolimus in de Novo Kidney Transplant Recipients

CompletedNCT01410448

Novartis PharmaceuticalsKidney Transplantation

Start: 2011-11-30End: 2015-12-31Updated: 2017-06-16

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

CompletedNCT02334488

Poitiers University HospitalChronic Kidney Disease

Start: 2014-12-11End: 2020-07-03Updated: 2021-01-29

Phase 4

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

CompletedNCT00574197

Cedars-Sinai Medical CenterGastrointestinal Symptoms, Heart Transplantation

Start: 2006-06-30End: 2009-12-31Updated: 2020-07-30

Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

CompletedNCT00646737

NovartisKidney Transplantation

Start: 2008-05-31End: 2008-12-31Updated: 2017-02-23

Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate

CompletedNCT01354301

Hospital do Rim e HipertensãoCytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection

Start: 2011-05-31End: 2014-12-31Updated: 2015-03-23

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

CompletedNCT01801280

Klemens BuddeDrug Interaction, Immunosuppression, Transplantation

Start: 2012-01-31End: 2014-03-31Updated: 2019-02-21

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)

CompletedNCT01822483

Irmandade Santa Casa de Misericórdia de Porto AlegreRenal Transplantation

Start: 2013-04-30End: 2015-03-31Updated: 2015-04-03

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

CompletedNCT02953873

Medical University of South CarolinaImmunosuppression

Start: 2017-05-05End: 2018-12-14Updated: 2019-12-26

A multicenter, open, prospective, randomized, parallel-group, 12-month trial of REduced immunosuppression for oLdEr AdultS kidnEy transplant recipients: the RELEASE study.

RecruitingCTIS2025-520535-16-00

Consorci Mar Parc De Salut De BarcelonaEnd-stage renal disease

Start: 2025-10-10Target: 270Updated: 2025-08-19

Related Papers

Étude PROspective, Multicentrique, randomisée, en ouvert, évaluant le bénéfice sur la fonction rénale à 12 mois post-transplantation, d’une immunosuppression avec sevrage de l’inhibiteur de la calcineurine à 3 mois et associant mycophénolate sodique-Evérolimus versus Tacrolimus-Evérolimus chez des patients transplantés rénaux de novo

Néphrologie & Thérapeutique2022-09-01

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients

Frontiers in Pharmacology2018-11-148 citations

320 Urine tweak protein is a novel biomarker for resistant-to-treat lupus nephritis

2017-03-014 citations

A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience

Lupus Science & Medicine2016-01-0114 citations

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses

American Journal of Transplantation2015-05-18154 citations

Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Renal Transplant Patients: Preliminary Results From NEVERWOUND Study.

Transplantation2014-07-012 citations